A new definition and classification of chronic kidney disease-mineral and bone disorder (CKD-MBD) was proposed in 2005 and it was later followed by a guideline publication on this topic from Kidney Disease: Improving Global Outcomes (KDIGO) in 2009. This work recognized that CKD-MBD is a syndrome of bone abnormalities, laboratory abnormalities, and vascular calcification linked to fractures, cardiovascular disease, and mortality. Because of limited data at the time of the original guideline systematic review, many of the recommendations were cautiously vague. KDIGO convened a Controversies Conference in October 2013 to review the CKD-MBD literature published since the 2009 guideline. Specifically, the objective of this conference was to determine whether sufficient new data had emerged to support a reassessment of the CKD-MBD guideline and if so to determine the scope of these potential revisions. This report summarizes the results of these proceedings, highlighting important new studies conducted in the interval since the original KDIGO CKD-MBD guideline.
Bibliographical noteFunding Information:
MK declared having received consultancy fees and speaker honoraria from Abbvie, Amgen, Fresenius, Medice, Mitsubishi, Sanofi, Shire, and Vifor. GJE declared having received consultancy fees from Amgen, Shire, and Vifor Australia; speaker honoraria from Amgen, Sanofi and Shire. PE declared having received consultancy fees from Amgen; speaker honoraria from Amgen, Astellas, Fresenius, and Shire; research support from Amgen. JHI declared having received consultancy fees from AstraZeneca and Keryx; speaker honoraria from Shire. SAJ declared having received consultancy fees from Amgen and Sanofi; speaker honoraria from Amgen, Bayer, Sanofi/Genzyme, and Warner Chilcott/Actavis. MHLP declared having received research support from Servier. RIT declared having received consultancy fees from Fresenius and research support from Kaneka. MAT declared having received research support from Abbott Laboratories through a peer reviewed grant to the Canadian Institutes of Health Research. DCW declared having received consultancy fees from Abbvie, Amgen, Astellas, Baxter, F Hoffmann-La Roche, Janssen, Merck Sharp & Dohme, Otsuka, and Vifor; research funding from AstraZeneca/British Heart Foundation, Kidney Research UK, Medical Research Council, Healthcare Quality Improvement Partnership; speaker honoraria from Amgen and Otsuka. BLK, MBL and RS reported no relevant disclosures.
© 2014 International Society of Nephrology.
- clinical practice guideline
- renal osteodystrophy